/
DNTH
$94.36-$0.99 (-1.04%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$5.2B
55M shares
52-week range
$17.27 – $97.38
96% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.33%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$83.36
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $1.5M | $6.4M | $2.8M | $6.2M | $2.0M |
| Cost of revenue | $875.0K | $1.8M | $2.0M | $0 | $0 | $0 | $0 | $0 |
| Gross profit | −$875.0K | −$1.8M | −$2.0M | $1.5M | $6.4M | $2.8M | $6.2M | $2.0M |
| Gross margin | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| R&D | $41.3M | $57.4M | $48.6M | $12.6M | $29.4M | $32.8M | $83.1M | $145.6M |
| Operating income | −$60.0M | −$83.0M | −$78.7M | −$13.1M | −$29.7M | −$48.2M | −$101.9M | −$177.9M |
| EBITDA | −$56.6M | −$74.9M | −$73.0M | −$11.1M | −$28.3M | −$43.2M | −$84.6M | −$161.9M |
| Net income | −$57.5M | −$76.8M | −$74.9M | −$13.1M | −$28.5M | −$43.6M | −$85.0M | −$162.3M |
| Net margin | — | — | — | -888.1% | -443.8% | -1541.2% | -1362.8% | -7973.3% |
| EPS (diluted) | -27.62 | -33.18 | -27.30 | -3.82 | -7.60 | -8.45 | -2.55 | -4.20 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1M | $-3.75 | $-4.72–$-3.05 | 9 |
| 2027 | $2M | $-4.48 | $-5.31–$-3.33 | 9 |
| 2028 | $18M | $-4.86 | $-5.89–$-2.59 | 11 |
| 2029 | $189M | $-2.84 | $-4.73–$-0.77 | 4 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Dianthus Therapeutics, Inc. Common Stock
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
www.dianthustx.com- Employees
- 92
- IPO / List date
- Sep 12, 2023
- HQ
- NEW YORK, NY
Held by traders on TradeandTell
No one on the platform currently holds DNTH.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 32,100 | $1.3M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded DNTH yet.
